巨子 ICON - 財經股票資訊及專家分析
搜尋 股票

Incyte Corp

INCY
最少15分鐘延遲,股票資訊由第三方資訊供應商提供
・Incyte Corp - 延遲價格・最後更新於 14/01 12:14
最高位
74.960
最低位
72.830
開市價
--
前收市價
73.660
成交量(千)
96.96
成交額(百萬)
63.01
買入
--
賣出
--
每手股數
--
市值(百萬)
16,535.87
市盈率
30.930
息率
--
差價
--
52週高低
101.470 - 61.910
所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

企業資料

公司名稱
Incyte Corp
證券代碼
INCY.US
所屬板塊
Biotechnology
公司業務
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). Incyte's pipeline includes a broad array of oncology and dermatology programs.
發行量
219876892
公司總部
1801 Augustine Cut-Off
公司網址
https://www.incyte.com
公司電郵
mbooth@incyte.com
公司電話
+1 302 498-6700
暫無內容

關於

Incyte Corp(INCY.US)所屬的行業板塊為Biotechnology。
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). Incyte's pipeline includes a broad array of oncology and dermatology programs.
詳細公司背景可參考: https://www.incyte.com